Siemens Healthineers stock joins cancer think tank, slightly lower pre-market
Published on 10/19/2026 at 08:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCompany news and trading agenda
- Siemens Healthineers joined a radiopharmaceutical think tank on October 18, 2026.
- Fourth-quarter results and the analyst call are scheduled for November 5, 2026.
- Siemens Healthineers stock trades pre-market at EUR 41.27 at 8:15 a.m. CEST at Lang & Schwarz on October 19, 2026, 0.43 percent below the Xetra close of October 16, 2026.
Simply Wall St reported on October 18, 2026, that Siemens Healthineers had joined the Prostate Cancer Foundation’s Radiopharmaceutical Think Tank. Siemens Healthineers stock trades pre-market at EUR 41.27 at 8:15 a.m. CEST at Lang & Schwarz on October 19, 2026, 0.43 percent below the Xetra close of October 16, 2026 (EUR 41.45).
Cancer research collaboration
The collaboration focuses on easing bottlenecks in the development and broader access of radiopharmaceutical cancer therapies across multiple tumor types, according to Simply Wall St. The report identifies Siemens Healthineers as a participant in the initiative.
Ahead of the Xetra open
The indication is EUR 0.18 below the Xetra reference. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Siemens Healthineers stock.
The group and its agenda
Siemens Healthineers develops healthcare products, services and solutions used in clinical decision-making and treatment pathways, as described on its Investor Relations page. The company lists fourth-quarter results and an analyst call for November 5, 2026. Market context: Market report DAX.
